ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Aug 19, 2024 · CIK: 1715925
Sentiment: neutral
Topics: sec-filing, 6-K, press-release
TL;DR
IPA files 6-K, check press release for August updates.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on August 19, 2024, to report a press release dated August 19, 2024. The filing is for the month of August 2024 and indicates the company will file annual reports under Form 20-F. The company's principal executive office is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Why It Matters
This filing serves as an official notification to the SEC and investors about the company's reporting status and includes a press release, which may contain important operational or financial updates.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release and confirm reporting status, without disclosing new material financial or operational information within the 6-K itself.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- August 19, 2024 (date) — Press Release Date and Filing Date
- 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (location) — Principal Executive Office Address
- Kristin Taylor (person) — Signatory for the filing
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report information to the SEC for the month of August 2024, specifically including a press release dated August 19, 2024.
What is the filing date of this report?
The filing date of this report is August 19, 2024.
Where is ImmunoPrecise Antibodies Ltd.'s principal executive office located?
ImmunoPrecise Antibodies Ltd.'s principal executive office is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Which form will the registrant use for its annual reports?
The registrant, ImmunoPrecise Antibodies Ltd., will file its annual reports under cover of Form 20-F.
What exhibit is included with this Form 6-K?
Exhibit 99.1, a Press Release dated August 19, 2024, is included with this Form 6-K.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-08-19 09:21:46
Filing Documents
- press_release_aug_18_202.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 29KB
- 0000950170-24-098298.txt ( ) — 50KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: August 19, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer